Background We evaluated the effect of dual, longacting inhaled bronchodilator treatment on
exacerbations in patients with severe and very severe chronic obstructive pulmonary …

We investigated the efficacy and safety of dual bronchodilation with QVA149 versus its
monocomponents indacaterol and glycopyrronium, tiotropium and placebo in patients with …

We evaluated the effect of QVA149, a dual bronchodilator combining indacaterol and
glycopyrronium, on direct patient-reported dyspnoea in patients with moderate-to-severe …

Background QVA149 is an inhaled, once-daily fixed-dose dual bronchodilator combination
of the long-acting β 2-agonist indacaterol and long-acting muscarinic antagonist …

Rationale: There are no studies on withdrawal of inhaled corticosteroids in patients on long-
term triple therapy in the absence of frequent exacerbations. Objectives: To evaluate the …

Background QVA149 is an inhaled fixed-dose combination therapy under development for
the treatment of chronic obstructive pulmonary disease (COPD). It combines indacaterol (a …

Rationale: Current Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy
recommends the combination of two long-acting bronchodilators of different pharmacologic …

Background The current Global initiative for chronic Obstructive Lung Disease (GOLD)
treatment strategy recommends the use of one or more bronchodilators according to the …

Background Evidence is scarce on the relative risk-benefit of inhaled triple therapy,
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β 2 …

Background We compared the efficacy and safety of indacaterol and tiotropium in patients
with severe chronic obstructive pulmonary disease (COPD) and a history of at least one …